ON4.MU Ono Pharmaceutical Co. Ltd
- Market cap
- EUR 6.02B
- P/E
- 14.1x
- P/B
- 1.21x
- ROE
- 11.1%
- Dividend yield
- 3.68%
- Fundamental score
- 3.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ON4.MU undervalued?
Graham numberON4.MU trades 12.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ono Pharmaceutical Co. Ltd fundamental analysis
18 of 22 checks passedROE 1/2
Moderate return on equity (11.1%), between 10% and 20%.
ROA 1/1
Return on assets (8.9%) is above the industry median (3.8%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (39.4%) is above the 5-year average (-0.4% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (39.4%) is above the industry median (14.7%).
Revenue Growth 1/2
Revenue grew 4.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (7.8%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 40.9x against interest expense, well covered.
PE vs Market 1/1
PE (14.1x) is below the market median (16.6x).
PE vs Industry 1/1
PE (14.1x) is below the industry median (16.6x).
PBV 1/1
Price to book (1.2x) is below the industry median (1.5x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 17.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (3.8%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 2/2
Dividends paid without a cut of more than 10% for 11 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 53.8%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Ono Pharmaceutical Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also p…
Full company profileOno Pharmaceutical Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ono Pharmaceutical Co. Ltd annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 245B | 262B | 289B | 292B | 309B | 361B | 447B | 503B | 487B | 516B | 465B |
| Gross Profit | 179B | 196B | 205B | 213B | 224B | 268B | 337B | 376B | 339B | 374B | 350B |
| Operating Income | 72.3B | 60.7B | 62.0B | 77.5B | 98.3B | 103B | 142B | 160B | 59.7B | 92.2B | 123B |
| EBITDA | - | 73.2B | 75.9B | 94.8B | 117B | 124B | 162B | 182B | 91.5B | 134B | 164B |
| Net Income | 55.8B | 50.3B | 51.5B | 59.7B | 75.4B | 80.5B | 113B | 128B | 50.0B | 69.8B | 96.6B |
| EPS | 105 | 98 | 100 | 120 | 151 | 165 | 231 | 272 | 107 | 148 | 206 |
| Balance Sheet | |||||||||||
| Total Assets | 617B | 609B | 655B | 673B | 747B | 739B | 882B | 914B | 1.06T | 1.11T | 1.08T |
| Total Liabilities | 93.3B | 79.6B | 92.3B | 105B | 106B | 77.5B | 135B | 115B | 276B | 250B | 212B |
| Shareholders' Equity | 519B | 524B | 557B | 562B | 636B | 656B | 742B | 793B | 782B | 851B | 867B |
| Cash & Short-term Investments | 146B | 65.3B | 60.0B | 69.0B | 61.0B | 69.1B | 96.1B | 166B | 205B | 237B | 220B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 74.5B | 15.7B | 66.8B | 74.2B | 74.0B | 61.8B | 160B | 111B | 82.5B | 137B | 4.21B |
| Capital Expenditure | 14.8B | 15.6B | 22.3B | 7.48B | 7.02B | 5.50B | 14.5B | 20.8B | 7.99B | 53.3B | 22.5B |
| Free Cash Flow | - | -14.1B | 37.2B | 51.7B | 53.7B | 49.6B | 145B | 89.8B | 74.5B | 83.6B | -18.3B |
| Ratios | |||||||||||
| ROE | 10.7% | 9.6% | 9.2% | 10.6% | 11.9% | 12.3% | 15.2% | 16.1% | 6.4% | 8.2% | 11.1% |
| ROA | 9.0% | 8.3% | 7.9% | 8.9% | 10.1% | 10.9% | 12.8% | 14.0% | 4.7% | 6.3% | 8.9% |
| Net Profit Margin | 22.8% | 19.2% | 17.9% | 20.4% | 24.4% | 22.3% | 25.2% | 25.5% | 10.3% | 13.5% | 20.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ono Pharmaceutical Co. Ltd dividends
- Dividend yield
- 3.68%
- Forward dividend
- 0.45 EUR
- Payout ratio
- 53.8%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 37.5B | 80 | 53.8% |
| 2025 | JPY 37.5B | 80 | 75.0% |
| 2024 | JPY 37.2B | 79 | 29.1% |
| 2023 | JPY 29.7B | 61 | 26.4% |
| 2022 | JPY 27.7B | 57 | 34.4% |
| 2021 | JPY 22.4B | 45 | 29.8% |
| 2020 | EUR 22.8B | 46 | 38.1% |
| 2019 | EUR 21.8B | 42 | 42.4% |
| 2018 | EUR 23.4B | 46 | 46.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Mar 29, 2016.
Who owns Ono Pharmaceutical Co. Ltd
- Insiders 11.99%
- Institutions 40.58%
- Public & others 47.43%
- Shares outstanding 470M
- Free float 454M
Ono Pharmaceutical Co. Ltd company profile
- Company name
- Ono Pharmaceutical Co. Ltd
- Ticker
- ON4.MU
- Exchange
- Munich Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,206
- Fiscal year end
- March
- Address
- 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564
- Phone
- 81 6 6263 5670
- Website
- ono-pharma.com
About Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Ono Pharmaceutical Co. Ltd management
10- Mr. Gyo SagaraCEO & Chairman of the Board · born 1958
- Mr. Toichi Takino Ph.D.President, COO & Representative Director · born 1968
- Mr. Toshihiro TsujinakaCorp Sr Ex Off, Chief CMC & Prod, Dig Tech, Glob Qual, Bus Trans Dept Off, Bus Des/Chief Off and Dir · born 1964
- Mr. Masaki ItoCorporate Executive Officer, Chief Officer of Fin. & Accounting div.
- Ryuta ImuraVice President of Corporate Communications
- Mr. Kunihiko ItoCorporate Officer & Head of Global Business
- Hitoshi MitoCorporate Officer, Exe. VP of Digital Tech. and VP of IT Strategy & DX
- Seishi Katsumata Ph.D.Corporate Officer and Executive Director of Discovery & Research
- Harumi NakanoCorporate Officer, EVP of Finance & Accounting Division & VP Finance & Accounting Department
- Satoshi TakahagiVice President of Sustainability Promotion & Corporate Officer